{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-016041","form_type":"8-K","ticker":"INBP","cik":"0001016504","company_name":"INTEGRATED BIOPHARMA INC","filed_at":"2024-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.895346+00:00","generated_at":"2026-06-02T03:10:44.485432+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Integrated BioPharma Q3 net income $0.3M vs $16k YoY; revenue flat at $13.1M","bullets":["Quarterly revenue $13.1M (flat YoY); operating income $0.4M vs $44k prior year.","Net income $0.3M ($0.01 diluted EPS) vs $16k ($0.00) in Q3 2023.","Nine-month revenue $37.6M (down 0.3% YoY); net loss $0.2M ($0.01 loss per share).","Two largest contract manufacturing customers represent ~90% of total revenue; management plans to expand customer base by FY2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-016041","json":"https://secwatch.observer/filing/0001437749-24-016041.json","markdown":"https://secwatch.observer/filing/0001437749-24-016041.md","text":"https://secwatch.observer/filing/0001437749-24-016041.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1016504/000143774924016041/0001437749-24-016041-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1016504/000143774924016041/inbp20240509_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T03:10:44.485432+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ef6d8222cc85cf8f3d5edf3ab939919680396cb3","claim":"INTEGRATED BIOPHARMA INC reported quarter ended March 31, 2024 results: revenue $13.1 million, net income $0.3 million, EPS $0.01.","evidence_excerpt":"(the “Company” or “INBP”) reports its financial results for the quarter ended March 31, 2024. Revenue for each of the quarters ended March 31, 2024 and 2023 were approximately $13.1 million. The Company had operating income for the quarter ended March 31, 2024 and 2023 of approximately $0.4 million and $44,000, respectively. Revenue for the nine-month period ended","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1016504/000143774924016041/0001437749-24-016041-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended March 31, 2024"},{"label":"Revenue","value":"$13.1 million"},{"label":"Net income","value":"$0.3 million"},{"label":"EPS","value":"$0.01"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}